/EINPresswire.com/ -- ALACHUA, FL--(Marketwired - December 08, 2016) - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that its Senior V.P. for Medical Affairs, Dr. Sharon Hrynkow, will present "Use of Cyclodextrins in Compassionate Programs and Clinical Trials for Niemann Pick Disease Type C" as part of a panel discussion titled Pediatrics: Latest Advances in Diagnosis and Therapy at the BioFlorida Annual Conference. The presentation will cover the use of Trappsol® Cyclo™, CTD's proprietary formulation of hydroxypropyl beta cyclodextrin, in the treatment of Niemann Pick Disease Type C.

"We are excited to report on the progress in our clinical programs in the US and Europe to colleagues in the Florida life sciences business community," said N. Scott Fine, CTD Chairman and CEO.

Presentation Details:

Date: Tuesday, December 13^th

Time 11:10 am EST

Location: Hyatt Regency Jacksonville Riverfront

Niemann-Pick Disease Type C is a rare and fatal genetic disease that impacts primarily children but is increasingly diagnosed in older patients who may live with disability for many years. The disease impacts the brain and major organs through abnormal accumulation of cholesterol in cells.

About CTD Holdings:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com

About the BioFlorida Conference:
BioFlorida is the voice of Florida's life sciences industry, representing nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians. The Annual Conference is BioFlorida's largest and most comprehensive event of the year featuring an informative program showcasing science, business and public policy issues. Conference Dates: Sunday-Tuesday, December 11-13, 2016. To view the agenda and to register to attend, please go to BioFlorida's website: www.bioflorida.com.

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.